Recently, experts from the field of pulmonary arterial hypertension (PAH) throughout the country conducted an in-depth discussion on the significance and therapeutic effect of Anlishengtan in China. The experts believe that as a new type of highly selective endothelin receptor antagonist, this drug has brought new therapeutic options for PAH patients in China.
PAH is a rare disease that is unfamiliar to the public but is extremely malignant. About 15 to 25 people per 1 million people suffer from the disease. It can occur at any age and gender, usually more than 70% of patients are young people, and the incidence of women is about 2 times higher than men. The disease started to hide and develop slowly. The earliest symptoms of a patient are usually feeling breathing difficulties, fatigue, and heart palpitations during physical activity. As the disease progresses, the patient may even experience chest pain, cough, hemoptysis, and syncope. Most patients will die in 2 to 3 years or even shorter if they cannot get the correct diagnosis and targeted treatment in time. Therefore, PAH is called "malignant tumor in cardiovascular disease".
Professor Jing Zhicheng from Tongji University Affiliated Shanghai Pulmonary Hospital said: “A large number of basic and clinical studies in the world show that after one month of treatment with PAS in patients with PAH, their exercise capacity, palpitations and fatigue will be greater. Improvement; The patient's benefit will increase further after insisting on long-term treatment."
Anrisettan is a highly selective endothelin receptor antagonist that can prevent altered vasoconstriction of blood vessels by acting on endothelin and its receptors in patients with pulmonary hypertension, thereby alleviating disease symptoms and improving the quality of life of patients. Improve the living conditions. The efficacy and safety of this drug in patients with PAH have been confirmed in the 12-week, phase III, multicenter, randomized, double-blind, placebo-controlled study of ARIES-1 and ARIES-2. The 202 PAH patients enrolled in the ARIES-1 study were mainly from US and Australian research centers. Patients were randomized to receive either ambrisentan 5 mg or 10 mg once daily or placebo for 12 weeks; 192 PAH patients enrolled in the ARIES-2 study. Patients were mainly from European research centers. Patients were randomized to receive either 2.5 mg or 5 mg of ambrisol once daily or placebo. The primary endpoint for both studies was a change from baseline in placebo-corrected 6-minute walking distance (6 MWD) after 12 weeks of treatment. The results showed that ambrisentan treatment significantly improved the patient's 6MWD assessed exercise tolerance. At week 4 of treatment, an increase in 6MWD was observed in each dose group of ambrisentan and was maintained at week 8 and week 12; whereas the 6MWD was reduced at week 12 in the placebo group.
In the long-term extension study of ARIES-1 and ARIES-2, the ARIES-E study (not double-blind), patients in the placebo group in the ARIES-1 and ARIES-2 studies also entered the drug treatment group and were included in the treatment 383 patients. The main results of the study showed that: Anrishengtan improved the 6MWD and Borg dyspnea index for 2 years; improved or maintained the cardiac function class; delayed clinical deterioration time (83% of patients without clinical deterioration in 1 year) 72% in 2 years; improved survival in patients with PAH (94% survival rate at 1 year, 88% at 2 years), much higher than the NIH estimated survival of PAH patients Rate (72% for 1 year, 61% for 2 years). At the same time, the study confirmed the safety of anrigentan: the annual incidence of abnormal liver function in 2 years of treatment is only 2%.
"Anritsutan does not affect patients taking other drugs, which is commendable in the treatment of similar pulmonary hypertension. After entering the clinical practice in China, the drug will significantly improve the current situation of clinical treatment of this disease's "struggling" situation. Professor Jing Zhicheng added.
At present, the European Society of Cardiology guidelines for the diagnosis and treatment of pulmonary hypertension have listed Anritsu as the highest recommended drug for treatment of pulmonary hypertension.
PAH is a rare disease that is unfamiliar to the public but is extremely malignant. About 15 to 25 people per 1 million people suffer from the disease. It can occur at any age and gender, usually more than 70% of patients are young people, and the incidence of women is about 2 times higher than men. The disease started to hide and develop slowly. The earliest symptoms of a patient are usually feeling breathing difficulties, fatigue, and heart palpitations during physical activity. As the disease progresses, the patient may even experience chest pain, cough, hemoptysis, and syncope. Most patients will die in 2 to 3 years or even shorter if they cannot get the correct diagnosis and targeted treatment in time. Therefore, PAH is called "malignant tumor in cardiovascular disease".
Professor Jing Zhicheng from Tongji University Affiliated Shanghai Pulmonary Hospital said: “A large number of basic and clinical studies in the world show that after one month of treatment with PAS in patients with PAH, their exercise capacity, palpitations and fatigue will be greater. Improvement; The patient's benefit will increase further after insisting on long-term treatment."
Anrisettan is a highly selective endothelin receptor antagonist that can prevent altered vasoconstriction of blood vessels by acting on endothelin and its receptors in patients with pulmonary hypertension, thereby alleviating disease symptoms and improving the quality of life of patients. Improve the living conditions. The efficacy and safety of this drug in patients with PAH have been confirmed in the 12-week, phase III, multicenter, randomized, double-blind, placebo-controlled study of ARIES-1 and ARIES-2. The 202 PAH patients enrolled in the ARIES-1 study were mainly from US and Australian research centers. Patients were randomized to receive either ambrisentan 5 mg or 10 mg once daily or placebo for 12 weeks; 192 PAH patients enrolled in the ARIES-2 study. Patients were mainly from European research centers. Patients were randomized to receive either 2.5 mg or 5 mg of ambrisol once daily or placebo. The primary endpoint for both studies was a change from baseline in placebo-corrected 6-minute walking distance (6 MWD) after 12 weeks of treatment. The results showed that ambrisentan treatment significantly improved the patient's 6MWD assessed exercise tolerance. At week 4 of treatment, an increase in 6MWD was observed in each dose group of ambrisentan and was maintained at week 8 and week 12; whereas the 6MWD was reduced at week 12 in the placebo group.
In the long-term extension study of ARIES-1 and ARIES-2, the ARIES-E study (not double-blind), patients in the placebo group in the ARIES-1 and ARIES-2 studies also entered the drug treatment group and were included in the treatment 383 patients. The main results of the study showed that: Anrishengtan improved the 6MWD and Borg dyspnea index for 2 years; improved or maintained the cardiac function class; delayed clinical deterioration time (83% of patients without clinical deterioration in 1 year) 72% in 2 years; improved survival in patients with PAH (94% survival rate at 1 year, 88% at 2 years), much higher than the NIH estimated survival of PAH patients Rate (72% for 1 year, 61% for 2 years). At the same time, the study confirmed the safety of anrigentan: the annual incidence of abnormal liver function in 2 years of treatment is only 2%.
"Anritsutan does not affect patients taking other drugs, which is commendable in the treatment of similar pulmonary hypertension. After entering the clinical practice in China, the drug will significantly improve the current situation of clinical treatment of this disease's "struggling" situation. Professor Jing Zhicheng added.
At present, the European Society of Cardiology guidelines for the diagnosis and treatment of pulmonary hypertension have listed Anritsu as the highest recommended drug for treatment of pulmonary hypertension.
New keys cannot be created without key blanks. Key blank packages ensure you have key blanks of all shapes and sizes that are ready to be cut to the perfect specifications. Made of brass. Surface support electroplating. A variety of key slots are available. Brass Key, high quality. Different thickness, different length.
Design Blank Key,Blank Safe Key,Master Lock Key Blanks,Safe Blank Key
ANDJA TRADING PET. LTD. , https://www.lock-cylinder.com